News
Once-Monthly MariTide Shows Promising Weight Loss in Obesity and Type 2 Diabetes: Phase 2 Trial
MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. This unique mechanism targets key metabolic pathways involved in appetite regulation, insulin sensitivity, and weight management.
A once-monthly jab cuts body weight by 16% in groundbreaking obesity trial
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful treatment for obesity. With just a once-monthly shot of 'MariTide,' participants in the study lost as much as 16% of their body weight over the course of a year.
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...
4h
A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.
Zacks.com on MSN4h
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback